Apollo Hospitals Enterprise, a healthcare service provider, reported its results for Q1FY22 with an operating revenue of Rs. 3760 Cr, an increase by 73% Y-o-Y compared to Q1FY21 and an increase by 31% Q-o-Q compared to Q4FY21
The EBITDA of the company decreased in the quarter to 13.83% from 14.36% in the previous quarter (Q4FY21). Comparison with the corresponding period of previous year (Q1FY21) is not possible because the stringent lockdowns in the country on account of the first wave of the pandemic
The PAT of the company in the quarter increased to Rs. 504.83 Cr compared to Rs. 152.77 Cr in the previous quarter – An increase by 230.45% Q-o-Q. The loss in the corresponding quarter of the previous year was Rs. 203.61 Cr
During the quarter, the company recorded an exceptional gain of Rs. 294 Cr on remeasurement of previously held equity interest of Gleneagles Development Pte Ltd (a subsidiary) in its joint venture at its fair value post-acquisition of its balance stake
At the peak of the covid wave, the company allocated around 5000 beds for covid patients
Apollo Hospitals is largest private vaccinator for covid vaccines with 30% of all private vaccinations
The company has been able to perform 3.87 million covid vaccinations till date
Out of the total hospital revenues, the company has earned Rs. 490 Cr through treatment of Covid-19 patients
Apollo 24x7, the company’s online platform has 10 million unique users registered on the platform
The company had more than 15000 teleconsultations per day during the peak of the second wave of Covid
The company is currently doing 30000 deliveries a day in June 2021 in the pharmacy segment
Currently, 5% of the pharmacy revenue is earned through online sales by the company
The company acquired 47 lakh new customers during the quarter through either of their segments
Tier 2 city hospitals have also performed well during the quarter
The company expects margins to increase to around 23% in the future through healthcare services segment
Transport and airlines opening up is assuring the company of pent-up demand in the future for elective surgeries and medical tourism. This is a high margin and high APROB business
The Apollo brand is very strong and the company expect it to bring a large number of customers especially while expanding to newer cities in the future
The margin of newer hospitals can be expected to go up to 20% in the next 3-4 years and mature hospital to go up to 25-26%
You like to know more. We like that!
Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs 7499/Year.
Please login to view this free article.
This blog is available only for logged in users, please register and get access to view this article.